{"id":"fulvestrant-plus-goserelin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"},{"rate":"20-30%","effect":"Hot flashes"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"20-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fulvestrant works by binding to the estrogen receptor and promoting its degradation, thereby inhibiting estrogen-dependent breast cancer cell growth. Goserelin, on the other hand, acts on the hypothalamus to suppress the release of gonadotropin-releasing hormone, which in turn reduces the production of estrogen in the ovaries. This dual mechanism of action makes Fulvestrant plus Goserelin a promising treatment for hormone receptor-positive breast cancer.","oneSentence":"Fulvestrant is a selective estrogen receptor degrader that inhibits estrogen receptor-positive breast cancer cell growth, while Goserelin is a gonadotropin-releasing hormone receptor antagonist that suppresses estrogen production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:00:46.747Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic hormone receptor-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT05161195","phase":"PHASE4","title":"Roll-over Study to Allow Continued Access to Ribociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-07","conditions":"Metastatic Breast Cancer","enrollment":134},{"nctId":"NCT07340619","phase":"PHASE2","title":"Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-18","conditions":"Metastatic (Stage IV) Melanoma","enrollment":51},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT05063786","phase":"PHASE3","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2021-09-14","conditions":"Advanced Breast Cancer","enrollment":27},{"nctId":"NCT05870579","phase":"PHASE1","title":"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-11-13","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT05625087","phase":"PHASE2","title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2023-10-19","conditions":"Breast Cancer Stage IV","enrollment":162},{"nctId":"NCT02476786","phase":"PHASE2","title":"Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-17","conditions":"Breast Cancer, Cancer of Breast, Breast Neoplasms","enrollment":50},{"nctId":"NCT04657679","phase":"PHASE4","title":"Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2021-05-20","conditions":"Breast Cancer","enrollment":21},{"nctId":"NCT04862143","phase":"PHASE2","title":"Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-08","conditions":"Advanced Breast Cancer","enrollment":2},{"nctId":"NCT05720260","phase":"PHASE2","title":"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2023-01-17","conditions":"Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer","enrollment":42},{"nctId":"NCT06447623","phase":"PHASE3","title":"Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-02-01","conditions":"Advanced Breast Cancer, HR+/HER2- Breast Cancer","enrollment":184},{"nctId":"NCT02344472","phase":"PHASE3","title":"Detect V / CHEVENDO (Chemo vs. Endo)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2015-09","conditions":"Metastatic Breast Cancer","enrollment":271},{"nctId":"NCT01942135","phase":"PHASE3","title":"Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-26","conditions":"Metastatic Breast Cancer","enrollment":521},{"nctId":"NCT03007979","phase":"PHASE2","title":"Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-06-15","conditions":"Breast Cancer, Breast Carcinoma, Cancer of Breast","enrollment":55},{"nctId":"NCT05949541","phase":"PHASE2","title":"Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-07-26","conditions":"Breast Cancer, Advanced Breast Cancer","enrollment":265},{"nctId":"NCT05983107","phase":"PHASE2","title":"Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-07-20","conditions":"HR+/HER2- Advanced Breast Cancer, Targeted Therapy","enrollment":102},{"nctId":"NCT02333370","phase":"PHASE1","title":"A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-02-04","conditions":"Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer","enrollment":88},{"nctId":"NCT03447132","phase":"PHASE3","title":"Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant","status":"COMPLETED","sponsor":"International Cancer Research Group, United Arab Emirates","startDate":"2017-12-20","conditions":"Breast Neoplasm Female","enrollment":354},{"nctId":"NCT01989780","phase":"PHASE2","title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2014-01","conditions":"Metastatic Breast Cancer","enrollment":160},{"nctId":"NCT05438810","phase":"PHASE3","title":"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2022-01-18","conditions":"Advanced Breast Cancer, Female Breast Cancer","enrollment":312},{"nctId":"NCT02626507","phase":"PHASE1","title":"Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer","status":"UNKNOWN","sponsor":"Hoffman Oncology","startDate":"2016-01","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT05004142","phase":"PHASE2","title":"Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2020-06-30","conditions":"Breast Neoplasms","enrollment":70},{"nctId":"NCT03591549","phase":"PHASE4","title":"Fulvestrant in Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-08-01","conditions":"Metastatic Breast Cancer","enrollment":30},{"nctId":"NCT01266213","phase":"PHASE2","title":"Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2010-12","conditions":"Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal","enrollment":147},{"nctId":"NCT02072512","phase":"PHASE2","title":"The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Hospital Affiliated to Military Medical Science, Beijing","startDate":"2014-01","conditions":"Metastatic Breast Cancer","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anastrozole plus Goserelin"],"phase":"phase_2","status":"active","brandName":"Fulvestrant plus Goserelin","genericName":"Fulvestrant plus Goserelin","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fulvestrant is a selective estrogen receptor degrader that inhibits estrogen receptor-positive breast cancer cell growth, while Goserelin is a gonadotropin-releasing hormone receptor antagonist that suppresses estrogen production. Used for Metastatic hormone receptor-positive breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}